Not applicableLooking for participantsNCT07822100
What this trial is testing
To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
Who this might be right for
IgA Nephropathy (IgAN)Henoch Schönlein Purpura Nephritis
Hong Zhang 374